Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ImClone VEGF Development Program Expands, Gains Insurance With UCB Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Fifty-fifty partnership will co-develop UCB’s CDP-791 for use in solid tumors while ImClone continues work on in-house oncologic IMC-1121B.

You may also be interested in...

ImClone Opts Out Of Anti-VEGF Deal With UCB To Focus On Proprietary Compound

ImClone will develop IMC-1121B after the biologic demonstrated promising clinical activity in Phase I, firm says.

Spectrum’s Iso-Vorin Could Clear FDA For Osteosarcoma By First Quarter

The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts